Financials
Financial year 2025
Sightera Biosciences from Heist-op-den-Berg, company number BE1018457141, closed financial year 2025 with a result of € 41,452 after tax. For that financial year Sightera Biosciences recorded a gross margin of € 42,079 and equity of € 47,452. The company is profitable. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on May 4, 2026.
€ 47,452
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 41,452
Profit after tax over the fiscal year.
€ 42,658
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 41,452.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 15,385
Supplier invoices still open on the last day of the fiscal year.
Ask about Sightera Biosciences the way you would ask their accountant.
Answers from the filed annual accounts, the Belgian Official Gazette and the CBE register.
Connect ChatGPT or Claude for free- ChatGPT
- Claude
Free account, no payment card. Key figures unlimited, the annual accounts and deeds of 10 companies a month. Need more? Get in touch, we are looking for our first pilot users.
What happened to Sightera Biosciences?
What happened at Sightera Biosciences in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Capital increase of € 499,991, published in the Gazette. Source: Staatsblad ↗
- New annual accounts for financial year 2025: profit of € 41,452. Source: NBB ↗
- Incorporation, published in the Gazette. Source: Staatsblad ↗
- New establishment in Heist-op-den-Berg. KBO
- New establishment in Niel. KBO
- Maxim Le Compte became a director. NBB
- Lars Vanlommel became a director. NBB
- Hendrik Vercammen became a director. NBB
Management
Behind Sightera Biosciences are Maxim Le Compte, Lars Vanlommel and Hendrik Vercammen.
Directors
According to the 2025 annual accounts
Maxim Le Compte
Director
since 2025
Lars Vanlommel
Director
since 2025
Hendrik Vercammen
Director
since 2025
Establishments
Establishment units
Physical locations of this company
Wiekevorst-Dorp(WIE) 19
2222 Heist-op-den-Berg
Galileilaan 15
2845 Niel
Active since 9 January 2025
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Similar companies in the province of Antwerp
Same main activity (Speur- en ontwikkelingswerk op biotechnologisch gebied), 84 active companies in the province of Antwerp, largest first.
€ 303.4 million revenue · 2024 · Mechelen
€ 48.2 million revenue · 2025 · Mechelen
Eurofins Professional Scientific Services Belgium
€ 11.5 million gross margin · 2025 · Mechelen
€ 2.4 million gross margin · 2025 · Antwerpen
€ 2 million gross margin · 2025 · Kontich
€ 1.2 million gross margin · 2026 · Niel
Shareholders according to the Official Gazette deeds
Who contributed at incorporation and at capital increases, with the deed as source. Later share transfers are not published in the Gazette.
Incorporation
Source: Deed ↗- VERCAMMEN Hendrik(oprichter) 34.2%
- LE COMPTE Maxim(oprichter) 34.2%
- VANLOMMEL Lars(oprichter) 21.1%
- DEBEN Christophe(oprichter) 10.5%
Details
- Company number
- 1018.457.141
- VAT number
- BE 1018.457.141
- Registered office
- Wiekevorst-Dorp(WIE) 19, 2222 Heist-op-den-Berg
- Names & denominations
- Sightera Biosciences
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 9 January 2025
- Peppol
- Active · Active since 25 Aug 2025
- Activities · NACE
Speur- en ontwikkelingswerk op biotechnologisch gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied